Receptor News and Research

RSS

More insight into key receptor that influences effectiveness of serotonin-related antidepressants

University of Michigan scientists have provided the most detailed picture yet of a key receptor in the brain that influences the effectiveness of serotonin-related antidepressants, such as Prozac.

1 Jun 2010

Researchers identify body's natural self-repair mechanism that kicks in after spinal-cord injury

Researchers in the University of Alberta's Faculty of Rehabilitation Medicine have made an important discovery that could lead to more effective treatments for spinal-cord injuries. Karim Fouad and David Bennett have identified one of the body's natural self-repair mechanisms that kick in after injury.

31 May 2010

Adenosine plays major role in parlaying effects of acupuncture

Scientists have taken another important step toward understanding just how sticking needles into the body can ease pain.

31 May 2010

Women who undergo bilateral oophorectomy tend to have smaller tumors

More than half a million women in the United States undergo a hysterectomy each year and approximately half of those surgeries include removal of the ovaries. Researchers know that removing a woman's ovaries is associated with a reduction in the risk of developing breast cancer, but it has not been clear whether those cancers that do arise in these women differ from breast cancers in the general population.

29 May 2010

Researchers discover bitter taste inhibitor

Researchers have discovered a chemical that specifically blocks people's ability to detect the bitter aftertaste that comes with artificial sweeteners such as saccharin. The key is a molecule known only as GIV3727 that specifically targets and inhibits a handful of human bitter taste receptors, according to a report published online on May 27th in Current Biology, a Cell Press publication.

28 May 2010

Amorfix, Aragen Bioscience collaborate to develop high-affinity monoclonal antibodies against targets for cancer

Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes ("DSEs") on misfolded Fas receptor. Aragen will use those DSEs to generate highly specific monoclonal antibodies ("mAbs").

28 May 2010

Pfizer plans recruitment halt to EMPHASIS-HF trial

Pfizer Inc. announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules.

27 May 2010

Abnormal androgen signaling in ovaries cause female infertility

Male sex hormones, such as testosterone, have well defined roles in male reproduction and prostate cancer. What may surprise many is that they also play an important role in female fertility. A new study finds that the presence and activity of male sex hormones in the ovaries helps regulate female fertility, likely by controlling follicle growth and development and preventing deterioration of follicles that contain growing eggs.

27 May 2010

Blocking the activity of death receptor can stop tumor growth: New research study

Every cell contains machinery for self-destruction, used to induce death when damaged or sick. But according to a new research study, a receptor thought to mediate cell suicide in normal cells may actually be responsible for the unrestrained growth of cancerous tumors.

27 May 2010

Modified measles virus may hold potential for treatment of medulloblastoma

The use of modified measles virus may represent a new treatment for a childhood brain tumor known as medulloblastoma, according to a new study appearing in Neuro-Oncology.

27 May 2010

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2461629, titled, "HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS," which includes coverage of Amira's AM461 DP2 receptor antagonist.

27 May 2010

Bacteria may play wider role in people predisposed to obesity: Researchers

Bacteria may play more of a role in people predisposed to obesity than previously thought, according to studies presented today by University of Maryland School of Medicine researchers at the 110th general meeting of the American Society for Microbiology in San Diego.

27 May 2010

New book summarizes current state of research on NF-κB

NF-κB is a critical signaling molecule in the immune system that regulates cell survival and cell death, lymphocyte responses, and inflammation. Acting as a transcription factor that can receive several inputs, it coordinates distinct gene expression programs in response to a wide variety of stimuli.

26 May 2010

Silence Therapeutics deepens diverse portfolio of RNAi intellectual property

Silence Therapeutics plc announces the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO).

26 May 2010

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

GTx, Inc. today announced top line results of the Phase III clinical trial evaluating toremifene 20 mg, a selective estrogen receptor modulator, for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia, or PIN, a premalignant lesion of the prostate.

26 May 2010

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Clovis Oncology, Inc., a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents, and Avila Therapeutics, Inc., a biotechnology company designing targeted covalent drugs, announced today an agreement for the development and commercialization of Avila's epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program, currently in pre-clinical development for the treatment of non-small cell lung cancer (NSCLC).

25 May 2010

Researchers study how hematopoietic cells react when Epo levels increase

Our body reacts to blood loss by stimulating the production of red blood cells (erythrocytes). The cells of the hematopoietic (blood-forming) system in the bone marrow do so upon receipt of a signal by a hormone called erythropoietin, or Epo for short. This hormone is produced mainly by the kidney that increases the Epo level by up to a thousand-fold as a response to falling oxygen saturation of the blood.

25 May 2010

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX®) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 May 2010

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for vilazodone for the treatment of major depressive disorder.

24 May 2010

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Researchers testing a vaginal microbicide based on a new type of anti-HIV drug found it provided monkeys significant protection against infection with a virus similar to HIV, according to a study reported at the International Microbicides Conference in Pittsburgh today.

24 May 2010

Receptor News and Research

More insight into key receptor that influences effectiveness of serotonin-related antidepressants

Researchers identify body's natural self-repair mechanism that kicks in after spinal-cord injury

Adenosine plays major role in parlaying effects of acupuncture

Women who undergo bilateral oophorectomy tend to have smaller tumors

Researchers discover bitter taste inhibitor

Amorfix, Aragen Bioscience collaborate to develop high-affinity monoclonal antibodies against targets for cancer

Pfizer plans recruitment halt to EMPHASIS-HF trial

Abnormal androgen signaling in ovaries cause female infertility

Blocking the activity of death receptor can stop tumor growth: New research study

Modified measles virus may hold potential for treatment of medulloblastoma

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Bacteria may play wider role in people predisposed to obesity: Researchers

New book summarizes current state of research on NF-κB

Silence Therapeutics deepens diverse portfolio of RNAi intellectual property

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

Clovis Oncology, Avila Therapeutics announce development agreement for NSCLC EMSI program

Researchers study how hematopoietic cells react when Epo levels increase

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News